Dynavax Technologies Corporation $DVAX Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. has reduced its stake in Dynavax Technologies Corporation by 5.0%, now holding approximately 8.7 million shares valued at about $112.8 million.
• Analysts have shown optimism with JMP Securities and Wall Street Zen upgrading Dynavax Technologies' stock ratings to "market outperform" and "buy," respectively.
• Dynavax Technologies reported an earnings per share (EPS) of $0.14 for the last quarter, surpassing analyst estimates, with revenues of $95.44 million compared to an expected $87.55 million.

Vanguard Group Inc. cut its stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 5.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,698,183 shares of the biopharmaceutical company's stock after selling 459,901 shares during the quarter. Vanguard Group Inc. owned approximately 7.11% of Dynavax Technologies worth $112,815,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. raised its stake in shares of Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 1,169 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Dynavax Technologies during the 1st quarter worth approximately $30,000. GF Fund Management CO. LTD. acquired a new position in shares of Dynavax Technologies during the 4th quarter worth approximately $35,000. GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 3,627 shares during the period. Finally, Moloney Securities Asset Management LLC acquired a new position in shares of Dynavax Technologies during the 1st quarter worth approximately $131,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Scott Dunseth Myers bought 3,800 shares of the business's stock in a transaction on Friday, August 22nd. The stock was acquired at an average cost of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director directly owned 35,004 shares of the company's stock, valued at $378,743.28. The trade was a 12.18% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.98% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 target price on shares of Dynavax Technologies in a research note on Friday, August 22nd. Wall Street Zen raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Dynavax Technologies currently has an average rating of "Moderate Buy" and a consensus price target of $24.33.

Dynavax Technologies Price Performance

NASDAQ DVAX traded down $0.12 during mid-day trading on Wednesday, hitting $10.32. The stock had a trading volume of 81,866 shares, compared to its average volume of 2,084,253. The firm's 50 day moving average is $10.61 and its 200 day moving average is $11.36. Dynavax Technologies Corporation has a twelve month low of $9.22 and a twelve month high of $14.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -22.47 and a beta of 1.09.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The firm had revenue of $95.44 million during the quarter, compared to the consensus estimate of $87.55 million. Equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.